Monthly obstetrics and gynecology bulletin — September 18, 2026
Monthly obstetrics and gynecology bulletin — September 18, 2026
Period covered: August 18 to September 18, 2026. Ten verified items. A moderate-volume month: no new drug regulatory approvals or new phase 3 trials in gynecologic oncology; the strongest material is in contraception, ovarian cancer prevention and guidelines.
Obstetrics and maternal-fetal medicine
1. FDA grants breakthrough therapy designation to certolizumab pegol in antiphospholipid syndrome
[FDA regulatory] [USA / Belgium]
UCB announced on September 9 that the FDA (letter dated August 2026) granted Breakthrough Therapy Designation to certolizumab pegol (Cimzia, UCB) to prevent adverse placental outcomes in pregnant women with antiphospholipid syndrome and a positive lupus anticoagulant. It is based on IMPACT (NCT03152058), a phase 2, single-arm, open-label trial: certolizumab added to low-molecular-weight heparin and aspirin from week 8 to 28; in the efficacy population (n=45), 9 patients (20%; 95% CI 9.6–34.6) had the composite outcome (fetal death ≥10 weeks, preeclampsia with severe features, or placental insufficiency with delivery <34 weeks), lower than historical controls; median delivery at 36.5 weeks and neonatal survival 93%.
Why it matters: this is the first regulatory pathway specific to this population, but the data come from 45 patients with no concurrent control, and the designation is not an approval; the standard of care remains aspirin plus heparin. The biologic's cost puts it out of reach of the Dominican public system for now.
https://www.contemporaryobgyn.net/view/certolizumab-pegol-cimzia-fda-btd-antiphospholipid-syndrome-pregnancy
https://www.ucb.com/newsroom/press-releases/article/ucb-receives-us-fda-breakthrough-therapy-designation-for-cimziar-certolizumab-pegol-in-pregnant-women-with-antiphospholipid-syndrome-aps
2. Real-time artificial intelligence improves ultrasound detection of fetal intracranial malformations
[Clinical trial] [China]
A multicenter randomized crossover trial (the same sonographers with and without assistance) at five Chinese tertiary hospitals, published in The Lancet Digital Health and covered by MedSci on September 16. According to Omnicuris coverage, it included 1,584 high-risk singleton pregnancies (11–32 weeks); with the PAICS system, sensitivity for ten intracranial malformations (ventriculomegaly, holoprosencephaly, corpus callosum dysgenesis, among others) rose by 8.7 percentage points in the fetus-based analysis, and specificity met the prespecified 5% non-inferiority margin. According to MedSci, the benefit was greater among less-experienced operators.
Why it matters: this is one of the few randomized trials of AI in obstetric ultrasound; funding was not visible in the sources, and the system is validated only in a Chinese population, but the benefit in less-experienced operators is exactly what a country with a shortage of fetal-medicine specialists would need. (Source in Chinese.)
https://www.medsci.cn/article/show_article.do?id=acb595112e8d
https://www.omnicuris.com/medshots/daily_updates/ai-detection-fetal-intracranial-malformations-ultrasound_11-Sep-26_11-02
3. Aortic balloon occlusion (REBOA) versus tourniquet in conservative surgery for placenta accreta spectrum
[Publication] [Russia]
A single-center retrospective study from the Kulakov National Medical Research Center (Moscow), Akusherstvo i Ginekologiya 2026;8:83-92 (DOI 10.18565/aig.2026.106): 32 planned cesareans for accreta spectrum, REBOA (n=8) versus tourniquet compressive hemostasis (n=24). Median blood loss 725 mL [435–1,100] versus 2,225 mL [1,575–2,862] (p<0.001); surgical time 82.5 versus 151 min (p=0.035); hysterectomy 0/8 versus 6/24 (not significant); no balloon-related vascular complications. No funding declared.
Why it matters: this reinforces the trend favoring endovascular occlusion, but with only 8 patients in the intervention arm, no randomization; the authors themselves call it preliminary. It requires interventional radiology in the operating room, available in very few Dominican centers. (Source in Russian.)
https://aig-journal.ru/articles/sravnitelnaya-ocenka-effektivnosti-endovaskulyarnoi-ballonnoi-okkluzii-aorty-reboa-i-turniketnogo-gemostaza-pri-organosohranyaushih-operaciyah-u-pacie.html
4. One in four pregnancies with hyperglycemia: national study in Bangladesh
[Publication] [Bangladesh]
A cross-sectional study at 70 antenatal care centers across the country's 64 districts (The Lancet Regional Health – Southeast Asia, online September 10; DOI 10.1016/j.lansea.2026.100861). 6,631 pregnant women at 24–28 weeks with two-step screening (50 g GCT followed by 75 g OGTT, 2013 WHO criteria): gestational diabetes 19.4% and diabetes in pregnancy 8.1%; gestational diabetes 24.4% in urban areas versus 12.6% in rural areas. Independent factors: age ≥25, urban residence, high BMI, family history and physical inactivity. No external funding.
Why it matters: this figure is much higher than previously estimated burden (13%), with a large sample and standard criteria, although without adjustment for clustering and with a prior GCT that may underestimate. For the Caribbean, with rising obesity prevalence, it argues for universal screening with the OGTT.
https://pmc.ncbi.nlm.nih.gov/articles/PMC13584127
Gynecologic oncology
5. ACOG reinforces opportunistic salpingectomy to prevent epithelial ovarian cancer
[Guideline] [USA]
A clinical practice update from the Committee on Clinical Consensus (Obstetrics & Gynecology, August 25). Four recommendations: routine bilateral salpingectomy at every hysterectomy; recommend it in any gynecologic surgery entering the peritoneal cavity when fertility is not desired; complete salpingectomy as the preferred tubal procedure for permanent contraception; and support other surgeons in offering it during non-gynecologic surgery. It cites a meta-analysis with OR 0.48 (95% CI 0.33–0.69) and the 2026 British Columbia cohort (40,527 salpingectomies; serous cancer HR 0.22, 95% CI 0.05–0.95), with 12–16 additional minutes and no increase in complications. New: it no longer discourages changing the surgical approach to complete the salpingectomy.
Why it matters: the evidence remains observational, but it is consistent and the cost is minimal; this is one of the most applicable preventive interventions in our operating rooms, including postcesarean sterilization.
https://www.contemporaryobgyn.net/view/acog-clinical-update-salpingectomy-hysterectomy-ovarian-cancer-prevention
6. Updated network meta-analysis of PARP inhibitors in first-line maintenance
[Meta-analysis] [China]
Frontiers in Oncology, September 18 (PROSPERO CRD420261382266): 7 phase 3 trials, 3,930 patients with advanced, platinum-responsive ovarian cancer, including for the first time FZOCUS-1 (fuzuloparib). PFS benefit versus placebo was greatest in BRCAm (olaparib HR 0.30; 95% CI 0.22–0.40) and HRD+ (niraparib HR 0.45; 0.36–0.57), significant in HRD+ non-BRCA, inconsistent in HRP; no active regimen outperformed another, and no additional benefit was shown from adding an antiangiogenic (PAOLA-1 was excluded from the primary network); more grade ≥3 adverse events with PARPi. No commercial conflicts declared.
Why it matters: this does not change practice, but it synthesizes the state of the art with the correct reading: BRCA/HRD testing remains the key to indicating these drugs, whose access in the Dominican Republic remains limited.
https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2026.1884407/full
Reproduction and gynecologic endocrinology
7. Intrauterine mepivacaine reduces pain during IUD placement in nulliparous women
[Clinical trial] [Sweden]
JAMA (Elgemark et al., DOI 10.1001/jama.2026.14217; online September 17), Karolinska Institutet / Danderyd Hospital. A placebo-controlled multicenter randomized trial at 11 Swedish outpatient clinics, 370 nulliparous women aged 18 to 31 receiving a reduced-diameter IUD: intrauterine instillation of 10 mL of mepivacaine 20 mg/mL versus saline. According to OC Academy coverage, mean pain during placement (100-mm VAS, primary outcome) was 43.8 mm with mepivacaine versus 58.6 mm with placebo, a difference of 14.8 mm; the press release adds that tolerability improved.
Why it matters: this is a cheap, needle-free intervention that is reproducible in any clinic; the reduction is moderate (about 15 mm out of 100) and mean pain remains considerable with mepivacaine, so it does not replace other analgesic measures.
https://www.eurekalert.org/news-releases/1144042
https://www.ocacademy.in/blogs/intrauterine-mepivacaine-instillation-iud-pain
8. First Society of Family Planning guideline on deep or nonpalpable contraceptive implants
[Guideline] [USA]
A Committee Statement in Contraception (DOI 10.1016/j.contraception.2026.111567; released August 31, covered September 10). Standardized protocol: palpation; if either end cannot be palpated with certainty, imaging before any removal attempt (first-line ultrasound with a >10 MHz linear transducer; x-ray or MRI depending on radiopacity); no deep extraction attempt without localization and expert supervision; refer to experienced centers. Deep placement occurred in 8.8 per 1,000 insertions (95% CI 6.8–11.2); a quarter to half of referrals had prior failed attempts; U-technique with a modified clamp, success 98–100% suprafascial and 86–90% subfascial.
Why it matters: this is a consensus guideline, not a trial, but very timely with the etonogestrel implant now approved for 5 years; in our setting, the core message is do not "fish" blindly.
https://www.contemporaryobgyn.net/view/sfp-guidance-deep-nonpalpable-contraceptive-implant-removal-coe
9. Systematic review of endometriosis pharmacotherapy: dienogest and combined relugolix
[Publication] [Poland]
Journal of Clinical Medicine, September 17 (PROSPERO CRD420251183131), Medical University of Lublin: 44 studies from 926 records (2019–2025), a narrative synthesis without meta-analysis. It confirms dienogest as first line; combined relugolix therapy appears more effective and safer than elagolix or relugolix monotherapy (SPIRIT 1/2: dysmenorrhea responders 75% versus 29% with placebo); the evidence on immunotherapies is of very low certainty.
Why it matters: this brings no new data and the review's bar is modest; it serves as an updated map of options, with the caveat that oral GnRH antagonists still have limited access in the country.
https://www.mdpi.com/2077-0383/15/18/7238
Minimally invasive surgery and pelvic floor
10. Less pain after vNOTES hysterectomy than after conventional laparoscopy
[Publication] [Turkey]
Turkish Journal of Obstetrics and Gynecology, September 4 (DOI 10.4274/tjod.galenos.2026.45928), Sancaktepe Hospital, Istanbul: a retrospective cohort, 2021–2025, 192 benign hysterectomies (vNOTES 117, laparoscopy 75). Median VAS at 6 h 4 versus 6 and at 24 h 2 versus 3 (p=0.001); rescue analgesia 23.9% versus 60% (adjusted OR for laparoscopy 4.62; 95% CI 2.31–9.26); surgical time 86 versus 105 min and length of stay 1 versus 2 days. No funding.
Why it matters: the design is retrospective, single-center and without a sample-size calculation, but it is consistent with prior randomized evidence favoring the vaginal route; vNOTES is a low-instrumental-cost approach, attractive for Dominican centers with vaginal surgeons trained in it.
https://pmc.ncbi.nlm.nih.gov/articles/PMC13544008/
No verifiable items this month in prolapse and incontinence, nor from Japan, Korea, India, the Middle East or Latin America that cleared the quality filter.
Upcoming meetings and dates
XXV Latin American Congress of Obstetrics and Gynecology (FLASOG 2026): Lima, Peru, November 22–26, 2026 (precongress sessions on the 22nd). This is the year's regional meeting; it falls outside the six-week window, but is worth reserving. https://www.dmccongresos.com/xxvcongresolatinoamericanodeobstetriciayginecologia
Ready-to-paste LinkedIn post
Monthly obstetrics and gynecology bulletin — September 18, 2026 Ten verified items from the past 30 days, spanning obstetrics, gynecologic oncology, reproduction and minimally invasive surgery. Three worth your time: • FDA breakthrough therapy designation for certolizumab pegol in antiphospholipid syndrome: a first regulatory pathway for this population, based on a small, single-arm phase 2 trial. • ACOG update reinforcing opportunistic salpingectomy at hysterectomy and any peritoneal-entry gynecologic surgery to prevent ovarian cancer. • Intrauterine mepivacaine (JAMA) reduces pain during IUD placement in nulliparous women (mean 43.8 versus 58.6 mm on a 100-mm VAS), a cheap and reproducible option. Full bulletin: https://boletinesmedicos.com/en/obgyn/2026-09-18.html
Ready-to-paste X (Twitter) post
Monthly ob/gyn bulletin: FDA breakthrough therapy designation for certolizumab in antiphospholipid syndrome; ACOG reinforces opportunistic salpingectomy for ovarian cancer prevention; intrauterine mepivacaine cuts IUD-placement pain in JAMA trial. 10 verified items: https://boletinesmedicos.com/en/obgyn/2026-09-18.html
Get every issue by email
Free. One email with each new issue, with a short summary and links to the page and the audio. No ads inside the content: any sponsor is identified and has no say in the selection. We do not share your data; unsubscribe with a single message.